<DOC>
	<DOC>NCT02106793</DOC>
	<brief_summary>Primary objective - To compare the incidence of postoperative nasal synerchia between Mitomicin C and placebo in patients at 6 months after endoscopic sinus surgery - To validate the Thai version of disease-specific quality of life tool SNOT-22 Secondary objectives - To compare the clinical signs and symptoms of CRS in patients who receive Mitomicin C with those who receive placebo - To compare the disease-specific quality of life in patients who receive Mitomicin C with those who receive placebo - To compare the side effects of Mitomicin C versus placebo</brief_summary>
	<brief_title>Mitomicin C for Prevention Postoperative Endoscopic Sinus Surgery Synechia and QOL in Chronic Rhinosinusitis</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>All Thai adults (18 years and older) patients undergoing bilateral endoscopic sinus surgery for CRS Patients must not have following diseases or conditions Cystic fibrosis based on positive sweat test or DNA test Gross immunodeficiency (congenital or acquired) Congenital mucociliary problem (eg. Primary ciliary dyskinesia) Altered immune function such as patients with systemic vasculitis, systemic lupus erythematosus, end stage renal disease, cirrhosis, currently taking immunosuppressant or granulomatous disease Severe comorbidity with life expectancy of less than 1 year, such as advanced stage malignancy patient, or severe infection Patients are willing to participate and provide written informed consent (None)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic Rhinosinusitis</keyword>
	<keyword>Mitomicin C</keyword>
	<keyword>Postoperative nasal synerchia</keyword>
</DOC>